DiaMedica Therapeutics Inc. said it will implement a 1-for-20 consolidation of its outstanding common shares.
Shareholders approved the consolidation on Nov. 6.
Post-consolidation, the clinical-stage biopharmaceutical company will have about 7,856,875 common shares issued and outstanding.
The company's post-consolidation shares will begin trading on TSX Venture Exchange and the OTCQB marketplace on or about Nov. 15.
Minneapolis-based DiaMedica, which develops treatments for neurological and kidney diseases, is planning to list its shares on Nasdaq under the symbol DMAC.
